Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 16/20 | 0.65 |
| ▸ | RPS6KA1 | Q15418 | 14/20 | 0.65 |
| ▸ | RPS6KA5 | O75582 | 6/20 | 0.65 |
| ▸ | ROCK1 | Q13464 | 15/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | AKT2 | P31751 | 6/20 | 0.49 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | PRKCG | P05129 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | MARK3 | P27448 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3488757 | 0.96 | AKT1 (0.66) | AKT1RPS6KA1RPS6KA5ROCK1SLC2A1 | |
| Trifluoroacetic Acid SCHEMBL4247430 | 0.93 | AKT1 (0.66) | AKT1RPS6KA1RPS6KA5ROCK1SLC2A1 | |
| SCHEMBL4069034 | 0.93 | AKT1 (0.74) | AKT1RPS6KA1RPS6KA5ROCK1SLC2A1 | |
| Trifluoroacetic Acid SCHEMBL5063595 | 0.93 | AKT1 (0.62) | AKT1RPS6KA1RPS6KA5ROCK1SLC2A1 | |
| Trifluoroacetic Acid SCHEMBL5062985 | 0.92 | AKT1 (0.64) | AKT1RPS6KA1RPS6KA5ROCK1SLC2A1 | |
| Trifluoroacetic Acid SCHEMBL4244854 | 0.91 | AKT1 (0.63) | AKT1RPS6KA1RPS6KA5ROCK1SLC2A1 | |
| Trifluoroacetic Acid SCHEMBL5062862 | 0.90 | AKT1 (0.67) | AKT1RPS6KA1RPS6KA5ROCK1SLC2A1 | |
| Trifluoroacetic Acid SCHEMBL4072380 | 0.90 | AKT1 (0.67) | AKT1RPS6KA1RPS6KA5ROCK1SLC2A1 | |
| SCHEMBL4067805 | 0.89 | AKT1 (0.75) | AKT1RPS6KA1RPS6KA5ROCK1SLC2A1 | |
| Trifluoroacetic Acid SCHEMBL3487386 | 0.89 | AKT1 (0.57) | AKT1RPS6KA1RPS6KA5ROCK1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090227616-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION, A CORPORATION | 2009-09-10 | — | — | US | disclosed |
| EP-1653961-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080269131-A1 | Protein kinase B ; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(2S)-2-morpholinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; cancer and arthritis | SMITHKLINE BEECHAM CORPORATION | 2008-10-30 | — | — | US | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
| EP-1653961-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005011700-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227616-A1 | INHIBITORS OF AKT ACTIVITY | PI4KB, PIK3CA, AKT2 | AKT1 5/4885RPS6KA1 127/4885RPS6KA5 156/4885 |
| US-20080076763-A1 | Inhibitors of Akt activity | PI4KB, PIK3CA, AKT2 | AKT1 5/4885RPS6KA1 127/4885RPS6KA5 156/4885 |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | PI4KB, PIK3CA, AKT2 | AKT1 5/4885RPS6KA1 127/4885RPS6KA5 156/4885 |
| US-20080269131-A1 | Protein kinase B ; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(2S)-2-morpholinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; cancer and arthritis | MAP4K2, MAPKAPK2, PTK2B | AKT1 254/4885RPS6KA1 216/4885RPS6KA5 234/4885 |
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | AKT1 5/4885RPS6KA1 127/4885RPS6KA5 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.